Braveheart Bio announced its Q3 2026 financial results, highlighting $503.5 million in cash and investments, supporting operations through 2029. The company presented promising 52-week clinical data for its heart disease drug BHB-1893, showing improved patient outcomes and a simplified dosing regimen. Key Phase 3 trials for obstructive and non-obstructive hypertrophic cardiomyopathy are underway or planned, with interim and topline results expected in 2027. The company aims to deliver a best-in-class treatment with a straightforward dosing approach for patients with hypertrophic cardiomyopathy.
Braveheart Bio's Q3 2026 financial results and clinical updates provide context for health sector trading on Pluang. As of Nov 11, 2026 04:02 WIB, out of 150 priced health-sector US stocks, 52 rose and 97 fell. Ionis Pharmaceuticals Inc. (IONS) traded at USD 28.10 with a 1-day change of -9.35% and a typical hold time of 4 days, while Crispr Therapeutics AG (CRSP) was priced at USD 45.67, down 8.73% with a much longer typical hold time of 79 days and a dominant 99% sell order activity. Tango Therapeutics Inc. (TNGX) showed a contrasting 8.18% gain at USD 24.60 with balanced buy/sell activity and a short hold time of 4 days.
Cannabis Strategic Ventures has finalized its change of control with Scopien Technologies, an AI platform company, which now holds voting control through preferred stock. The company has appointed new leadership, including CEO Zameer Mulla, and plans...
Star Bulk Carriers Corp. has published its 2025 Environmental, Social and Governance (ESG) Report, its eighth annual report detailing the company's sustainability strategy, performance, and future objectives. The report, guided by the ESG Committee, ...
TELA Bio reported $19 million revenue in Q3 2026, down 8% year-over-year but with an 18% increase in international sales. The company reduced its operating loss by 21% sequentially and improved adjusted EBITDA loss by 55%, driven by a strategic cost ...
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
